ANXA5 and Huntington disease: As seen in the Figure 4D, we observed that the inhibition of HDAC8 in JAK2V617F-MSC induced significant decrease of viable CD34+ cells (Annexin V−/7AAD−) from both HD (p = 0.028) and JAK2V617F patients (p = 0.015).